FDA to streamline approvals of generic biologic drugs

The Food and Drug Administration is launching an effort to streamline the support process for cheaper alternative “biosimilar” versions of biologic drugs as a mode to curb wellness costs.  The bureau published a draft guidance for industry Wednesday that would perchance marque it faster and loss costly for companies to develop biologics and bring them to market, starring to accrued contention and little cause costs for patients.   The agency proposed that…